|Over a week ago|
Fly Intel: After-Hours Movers » 18:5807/1307/13/20
INMB, VNDA, FREQ, EW, BA, OSMT, ALT
Check out this evening's…
Frequency Therapeutics initiated with an Outperform at Oppenheimer » 16:1007/1307/13/20
Oppenheimer analyst Jay…
Oppenheimer analyst Jay Olson initiated coverage of Frequency Therapeutics with an Outperform rating and $36 price target. The analyst said that, given the substantial market opportunity and limited treatment options available, he believes Frequency's FX-322 holds the promise to "revolutionize" the treatment of hearing loss.
|Over a month ago|
Healthcare Financial Management Association to hold a virtual conference » 08:5606/2406/24/20
MTBC, NVZMY, NVS, NVAX, MRK, LOGI, REGN, RDY, FREQ, RCKT, TRVI, CSU, NVO
HFMA 2020 Digital Annual…
HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link
Thirteen new option listings and four option delistings on May 28th » 08:3005/2805/28/20
CFRX, FREQ, HARP, HOOK, HSTO, IFRX, KNSA, KZR, LQDA, OVID, PRVL, CNAT, CORV, CTRC, UNT
New option listings for…
New option listings for May 28th include ContraFect (CFRX), Centric Brands Inc (CTRCQ), Frequency Therapeutics Inc (FREQ), Harpoon Therapeutics Inc (HARP), HOOKIPA Pharma Inc (HOOK), Histogen Inc (HSTO), InflaRx NV (IFRX), Kiniksa Pharmaceuticals Ltd (Class A Stock) (KNSA), Kezar Life Sciences Inc (KZR), Liquidia Technologies Inc (LQDA), Ovid Therapeutics (OVID), Prevail Therapeutics Inc (PRVL), and Unit Corp (UNTCQ). Option delistings effective May 28th include Conatus Pharmaceuticals Inc (CNAT), Correvio Pharma Corporation (CORV), Centric Brands Inc (CTRC), and Unit Corp (UNT).
JPMorgan downgrades Frequency Therapeutics on unclear data timelines » 09:0405/1805/18/20
JPMorgan analyst Anupam…
JPMorgan analyst Anupam Rama downgraded Frequency Therapeutics to Neutral from Overweight with a price target of $27, down from $28. The analyst continues to believe that the company's lead asset FX-322 for sensorineural hearing loss has shown encouraging Phase 1/2 single dose data. However, 2020 appears to be turning out to be more of a clinical execution year for the company, Rama tells investors in a research note. Further, the primary clinical catalyst for the Frequency is Phase 2a single/repeat dose study results for which timelines are currently not well defined, adds the analyst. Rama believes enrollment completion and timelines to data "are in flux" in the midst of the COVID-19 pandemic, putting risk on the company's prior guidance of second half of 2020. Rama believes Frequency shares will perform in line with broader markets until timelines to data are better defined.
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan » 05:3305/1805/18/20
JPMorgan analyst Anupam…
JPMorgan analyst Anupam Rama downgraded Frequency Therapeutics to Neutral from Overweight with a $27 price target.
Frequency Therapeutics provides update on COVID-19 impact to business » 07:4405/1405/14/20
Frequency's offices are located in states that are currently under mandated lock down orders and/or stay at home advisories, though in Massachusetts, biotechnology firms have been deemed essential and are exempted from such orders. At present, the majority of Frequency employees are working from home, while certain necessary laboratory employees have periodically worked in the lab to ensure that essential experiments continue. The Farmington, Connecticut research site, co-located with the University of Connecticut, has paused activity and this site is expected to re-open when non-essential State offices are permitted to do so. Key experiments have been transitioned to the company's offices in Woburn, Massachusetts and third parties and contract research organizations have been engaged to advance certain projects.
Frequency Therapeutics reports Q1 EPS (16c), consensus (17c) » 07:4305/1405/14/20
Reports Q1 revenue…
Reports Q1 revenue $7.26M, consensus $5.86M. "Our Phase 2a study of FX-322 for sensorineural hearing loss continues to enroll subjects at a number of clinical sites, despite challenges from the COVID-19 pandemic. Overall, we are pleased with our progress and we deeply appreciate the work of our investigators, site staff and the engagement of the patients participating in the study during this challenging period," said Frequency Therapeutics CEO David Lucchino.
Frequency Therapeutics announces data from FX-322 exploratory clinical study » 07:1905/1405/14/20
Frequency Therapeutics announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent the active agents of FX-322 from reaching the cochlea. Further, the levels of FX-322 in the cochlea were predicted to reach the therapeutically active range of the treatment. FX-322 is Frequency's lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss, or SNHL. A Phase 1/2 study of FX-322 previously demonstrated statistically significant and clinically meaningful improvements in key measures of hearing function in patients with SNHL. The exploratory study, initiated late in 2019, was conducted at the Hannover Medical Centre in Hannover, Germany. Results were based on an analysis of cochlear fluid, known as perilymph, obtained intraoperatively from patients undergoing cochlear implant surgery. Each patient received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. In the study, seven subjects received a single dose of FX-322 at the same dose level given in the company's Phase 1/2 study and its ongoing Phase 2a study. Levels of both molecules that make up FX-322 were measured in all patients. The presence of round window membrane mucosal folds in certain subjects did not prevent the entry of FX-322 into the cochlea. Both agents that make up FX-322 were also predicted to achieve therapeutically active drug levels in the high frequency range of the cochlea, based on computer models. Study subjects were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed.
|Over a quarter ago|
Frequency Therapeutics management to meet with JPMorgan » 04:5502/1302/13/20
Meeting to be held in…
Meeting to be held in Chicago on February 13 hosted by JPMorgan.